SANUWAVE Health Announces 1-For-375 Reverse Stock Split
SANUWAVE Health announced a 1-for-375 reverse stock split effective from October 18, 2024. The common stock will trade on a split-adjusted basis under the symbol SNWV on the OTCQB, with a new CUSIP number, 80303D 305. This move will reduce the outstanding shares from approximately 1.18 billion to 3.15 million. Proportional adjustments will be made to equity awards, convertible notes, and warrants. No fractional shares will be issued; instead, fractional shares will be settled in cash. The reverse stock split will not change the total number of authorized shares or alter any stockholder's percentage interest in the company, except for adjustments due to fractional shares. Stockholders will receive transaction statements and information from the Securities Transfer regarding the exchange process.
SANUWAVE Health ha annunciato una frazione inversa delle azioni di 1 per 375 a partire dal 18 ottobre 2024. Le azioni ordinarie verranno scambiate su una base adeguata alla frazione sotto il simbolo SNWV sul OTCQB, con un nuovo numero CUSIP, 80303D 305. Questa operazione ridurrà le azioni in circolazione da circa 1,18 miliardi a 3,15 milioni. Verranno effettuate modifiche proporzionali ai premi azionari, ai note convertibili e ai warrant. Non verranno emesse azioni frazionarie; invece, le azioni frazionarie saranno liquidate in contante. La frazione inversa delle azioni non cambierà il numero totale di azioni autorizzate né altererà l'interesse percentuale di alcun azionista nella società, eccetto per le modifiche dovute alle azioni frazionarie. Gli azionisti riceveranno estratti conto e informazioni dalla Securities Transfer riguardo il processo di scambio.
SANUWAVE Health anunció un split inverso de acciones de 1 por 375 que entrará en vigor el 18 de octubre de 2024. Las acciones comunes se negociarán en una base ajustada por el split bajo el símbolo SNWV en el OTCQB, con un nuevo número CUSIP, 80303D 305. Esta medida reducirá las acciones en circulación de aproximadamente 1.18 mil millones a 3.15 millones. Se realizarán ajustes proporcionales a los premios de capital, notas convertibles y warrants. No se emitirán acciones fraccionarias; en su lugar, las acciones fraccionarias se liquidarán en efectivo. El split inverso de acciones no cambiará el número total de acciones autorizadas ni alterará el interés porcentual de ningún accionista en la compañía, excepto por los ajustes debidos a acciones fraccionarias. Los accionistas recibirán estados de transacciones e información de Securities Transfer sobre el proceso de intercambio.
SANUWAVE Health는 1대 375의 역 주식 분할이 2024년 10월 18일부터 시행된다고 발표했습니다. 보통주는 SNWV 기호로 OTCQB에서 분할 조정 기준에 따라 거래되며, 새로운 CUSIP 번호는 80303D 305입니다. 이 조치는 약 11억 8천만 주에서 315만 주로 발행 주식을 줄일 것입니다. 주식 보상, 전환사채 및 워런트에 대해 비례 조정이 이루어질 것입니다. 분할 주식은 발행되지 않으며, 대신 분할 주식은 현금으로 정산됩니다. 역 주식 분할은 총 승인된 주식 수를 변경하지 않으며, 주주의 회사에 대한 비율적 관심을 변경하지 않습니다. 다만, 분할 주식으로 인한 조정이 있을 수 있습니다. 주주들은 증권 이전 관련 거래 명세서 및 정보도 받을 것입니다.
SANUWAVE Health a annoncé un fractionnement inversé d'actions de 1 pour 375 qui sera effectif à partir du 18 octobre 2024. Les actions ordinaires seront échangées sur une base ajustée par le fractionnement sous le symbole SNWV sur le OTCQB, avec un nouveau numéro CUSIP, 80303D 305. Cette mesure réduira le nombre d'actions en circulation d'environ 1,18 milliard à 3,15 millions. Des ajustements proportionnels seront apportés aux primes en actions, aux obligations convertibles et aux bons de souscription. Aucune action fractionnaire ne sera émise ; au lieu de cela, les actions fractionnaires seront réglées en espèces. Le fractionnement inversé d'actions ne changera pas le nombre total d'actions autorisées ni n'altérera l'intérêt en pourcentage de tout actionnaire dans la société, à l'exception des ajustements dus aux actions fractionnaires. Les actionnaires recevront des relevés de transactions et des informations de la Securities Transfer concernant le processus d'échange.
SANUWAVE Health gab bekannt, dass am 18. Oktober 2024 ein 1-zu-375-Umkehrsplitt in Kraft treten wird. Die Stammaktien werden unter dem Symbol SNWV im OTCQB auf einer splittangepassten Basis gehandelt, mit einer neuen CUSIP-Nummer, 80303D 305. Dieser Schritt wird die ausstehenden Aktien von etwa 1,18 Milliarden auf 3,15 Millionen reduzieren. Proportionale Anpassungen werden für Eigenkapitalanreize, wandelbare Anleihen und Warrants vorgenommen. Es werden keine Bruchstücke von Aktien ausgegeben; stattdessen werden bruchstückhafte Aktien in bar abgewickelt. Der Umkehrsplitt wird die Gesamtzahl der genehmigten Aktien nicht ändern und auch nicht den prozentualen Anteil eines Aktionärs am Unternehmen verändern, mit Ausnahme von Anpassungen aufgrund von fractional shares. Aktionäre erhalten Transaktionsabrechnungen und Informationen von der Securities Transfer zum Austauschprozess.
- None.
- The reverse stock split will significantly reduce the number of outstanding shares from 1.18 billion to 3.15 million, which might indicate financial restructuring or challenges.
- Fractional shares resulting from the split will be settled in cash, potentially causing minor losses for some shareholders.
Common Stock Will Begin Trading on a Split-adjusted Basis on October 18, 2024
EDEN PRAIRIE, Minn., Oct. 16, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that, effective at 12:01 a.m. Mountain Time on October 18, 2024, the Company will implement a 1-for-375 reverse stock split of its outstanding common stock. The Company’s common stock will continue to trade under the symbol “SNWV” on the OTCQB and is expected to begin trading on a split-adjusted basis at the opening of the market on October 18, 2024, under a new CUSIP number, 80303D 305.
The reverse stock split will reduce the number of outstanding shares of Company common stock from approximately 1,181,272,961 shares to approximately 3,150,062 shares. Proportional adjustments will be made to the number of shares of SANUWAVE’s common stock subject to outstanding equity awards, convertible notes and warrants, as well as the applicable conversion or exercise price.
Information for SANUWAVE Stockholders
Upon the effectiveness of the reverse stock split, every 375 shares of issued and outstanding Company common stock at the close of business on October 17, 2024, will be automatically combined into one issued and outstanding share of common stock, with no change in par value per share. In connection with the reverse stock split, there will be no change to the total number of authorized shares of Company common stock as set forth in the Articles of Incorporation, as amended.
No fractional shares will be issued as a result of the reverse stock split. Any fractional shares that would have resulted from the reverse stock split will be settled in cash. The reverse stock split will affect all common stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s common stock, except to the extent that the reverse stock split results in some stockholders experiencing an adjustment of a fractional share as described above.
Record holders of Company common stock will receive a transaction statement with respect to the exchange of such shares for post-reverse split shares. Stockholders holding stock certificates will receive information from Securities Transfer Corporation (“STC”), the transfer agent for the Company’s common stock, regarding the process for exchanging their shares of common stock. STC will act as the exchange agent for the reverse stock split and may be contacted at (469) 633-0101.
For more information on the reverse stock split, please refer to the Company’s 2024 Consent Solicitation Statement, which can be accessed through the investor portion of the Company’s website at https://sanuwave.com/investors/ and on the Securities and Exchange Commission’s (“SEC”) EDGAR website, https://www.sec.gov/.
About SANUWAVE
SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
SANUWAVE's end-to-end wound care portfolio of regenerative medicine products and product candidates helps restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to expectations regarding the Company’s ability to effect, and the terms and timing of, the reverse stock split, the timing of future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect the Company’s ability to effect the reverse stock split, operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the SEC. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
FAQ
What is the effective date of SANUWAVE Health's 1-for-375 reverse stock split?
What will be the new CUSIP number for SANUWAVE Health after the reverse stock split?
How many shares will SANUWAVE Health have outstanding after the reverse stock split?
Will the reverse stock split affect my percentage ownership in SANUWAVE Health?
What happens to fractional shares resulting from SANUWAVE Health's reverse stock split?
